Trial Profile
A Phase 1 Open-Label, Parallel-Group, Adaptive, Single-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of GS-9674 in Subjects With Normal and Impaired Hepatic Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Cilofexor (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 01 May 2023 Results (n=56) assessing the pharmacokinetics, pharmacodynamic, safety, and tolerability of cilofexor in participants with normal hepatic function or hepatic impairment, published in the Journal of Clinical Pharmacology.
- 29 Aug 2020 Results evaluating the short- term safety, pharmacokinetics, and pharmacodynamics of Cilofexor in subjects with mild, moderate, or severe hepatic impairment presented at The International Liver Congress 2020
- 29 Oct 2018 Status changed from recruiting to completed.